CAMP4 Therapeutics Corporation received regulatory clearance from Australia's Therapeutic Goods Administration and local Human Research Ethics Committee to initiate a Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder. This regulatory milestone satisfies a condition in the company's September 2025 Securities Purchase Agreement, making the company eligible to receive up to $50.1 million in gross proceeds from a second closing of a private placement in exchange for up to 32,721,172 shares of common stock or pre-funded warrants. The second closing is expected to occur on or about August 3, 2026. CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics for genetic diseases.

At its June 10, 2026 annual meeting, stockholders approved an amendment to the 2024 Equity Incentive Plan to include outstanding pre-funded warrants in the evergreen provision calculation. Additionally, the Board approved a 2026 Inducement Plan allowing for the grant of up to 500,000 shares of common stock via various stock-based awards to new or rehired employees. The meeting also resulted in the election of Class II directors Steven Holtzman, Murray Stewart, and Richard Young, and the ratification of Ernst & Young LLP as the independent auditor. CAMP4 Therapeutics Corporation is a biotechnology company focused on developing therapeutics.